iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc.（ITOS）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · ITOS · 截至 2025年6月30日
股东结构概览
142
机构持有人数
▲ 8 vs Q1
$377.01M
机构持仓总市值
▲ $156.32M vs Q1
44.21M
总流通股
freeFloat 96.63%
37.81M
13F 申报持股数
▲ 848,138 vs Q1
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
ITOS 最大股东 · 机构持仓
Q2 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
ECOR1 CAPITAL, LLC biological products, (no diagnostic substances) | 10.69M | 24.54% | 24.54% | $106.57B | Aug 14, 2025 | NEW |
BLACKROCK, INC. biological products, (no diagnostic substances) | 4.57M | 10.50% | 10.50% | $45.61B | Aug 12, 2025 | ▲ 65.3K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 3.83M | 8.78% | 8.78% | $38.15B | Aug 14, 2025 | ▲ 1.14M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.66M | 3.82% | 3.82% | $16.59B | Aug 11, 2025 | ▼ 62.3K |
DIMENSIONAL FUND ADVISORS LP biological products, (no diagnostic substances) | 832.8K | 1.91% | 1.91% | $8.30B | Aug 12, 2025 | ▼ 348.5K |
BOXER CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 825.0K | 1.89% | 1.89% | $8.23B | Feb 17, 2026 | ▲ 825.0K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 703.5K | 1.61% | 1.61% | $7.02B | Aug 8, 2025 | ▲ 53.4K |
ORBIMED ADVISORS LLC biological products, (no diagnostic substances) | 700.0K | 1.61% | 1.61% | $6.98B | Aug 14, 2025 | NEW |
MARSHALL WACE, LLP biological products, (no diagnostic substances) | 611.6K | 1.40% | 1.40% | $6.10B | Aug 13, 2025 | ▲ 492.1K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 602.1K | 1.38% | 1.38% | $6.00B | Aug 13, 2025 | ▼ 43.5K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q2 2025 对比上季度
Q2 2025
26
增持
+5.15M 股15
新建仓
首次建仓9
减持
−2.84M 股0
清仓
完全退出净股数变化（前50家）
+2.30M
+5.15M / −2.84M
净新增持仓人
+32
新建 15 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
ITOS 内幕交易记录
数据来源：SEC Form 4
0
买入笔数
19
卖出笔数
0.00
买卖比
$2M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Call Matthew Chief Operating Officer | Aug 29, 2025 | D-Return | 135,937 | $7.05 | $958.4K | 0 | Form 4 ↗ |
Call Matthew Chief Operating Officer | Aug 29, 2025 | D-Return | 146,835 | $4.24 | $622.6K | 0 | Form 4 ↗ |
Call Matthew Chief Operating Officer | Aug 29, 2025 | D-Return | 66,170 | $2.95 | $195.2K | 0 | Form 4 ↗ |
Call Matthew Chief Operating Officer | Aug 29, 2025 | U-Tender | 161,898 | $10.05 | $1.63M | 0 | Form 4 ↗ |
Detheux Michel Chief Executive Officer | Aug 29, 2025 | D-Return | 52,700 | $6.16 | $324.6K | 0 | Form 4 ↗ |
Detheux Michel Chief Executive Officer | Aug 29, 2025 | D-Return | 444,815 | $7.05 | $3.14M | 0 | Form 4 ↗ |
Detheux Michel Chief Executive Officer | Aug 29, 2025 | D-Return | 185,000 | $4.24 | $784.4K | 0 | Form 4 ↗ |
Detheux Michel Chief Executive Officer | Aug 29, 2025 | U-Tender | 94,027 | $10.05 | $944.7K | 0 | Form 4 ↗ |
Lee David K director | Aug 29, 2025 | D-Return | 23,625 | $9.84 | $232.5K | 0 | Form 4 ↗ |
Feltquate David Chief Medical Officer | Aug 29, 2025 | U-Tender | 47,000 | $10.05 | $472.2K | 0 | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
iTeos Therapeutics, Inc.（ITOS）主要由机构投资者持有，机构持股比例约为 85.5%。公司内部人员持股约 3.37%，散户及公众持股约占剩余的 11.08%。
iTeos Therapeutics, Inc. 最大机构股东为 ECOR1 CAPITAL, LLC，截至 June 30, 2025 持有约 10.69 million 股，占总流通股的 24.54%。
目前共有 142 家机构持有 ITOS 股票，合计持仓市值约 $377,012,279，数据来源为最新 SEC 13F 申报。
常见问题
ITOS ownershipiTeos Therapeutics, Inc.（ITOS）主要由机构投资者持有，机构持股约 85.5%。最大股东为 ECOR1 CAPITAL, LLC，持股比例 24.54%。内部人员持股约 3.37%。数据来源 SEC Form 13F，截至 June 30, 2025。